These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1177 related items for PubMed ID: 20194844

  • 41. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM.
    J Clin Oncol; 2011 Sep 10; 29(26):3559-66. PubMed ID: 21844497
    [Abstract] [Full Text] [Related]

  • 42. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
    Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group.
    Lancet; 2010 Oct 02; 376(9747):1164-74. PubMed ID: 20888994
    [Abstract] [Full Text] [Related]

  • 43. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR, Munir T, McParland L, Rawstron AC, Chalmers A, Gregory WM, O'Dwyer JL, Smith A, Longo R, Varghese A, Smith A, Hillmen P.
    Health Technol Assess; 2017 May 02; 21(28):1-374. PubMed ID: 28628003
    [Abstract] [Full Text] [Related]

  • 44. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M.
    J Clin Oncol; 2012 Mar 20; 30(9):980-8. PubMed ID: 22331940
    [Abstract] [Full Text] [Related]

  • 45. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL.
    Oncologist; 2005 Feb 20; 10(2):150-9. PubMed ID: 15709217
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF.
    Cancer; 2004 May 15; 100(10):2181-9. PubMed ID: 15139062
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH.
    N Engl J Med; 2012 Aug 09; 367(6):520-31. PubMed ID: 22873532
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia.
    Wiernik PH, Adiga GU.
    Curr Med Res Opin; 2011 Oct 09; 27(10):1987-93. PubMed ID: 21905969
    [Abstract] [Full Text] [Related]

  • 53. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
    Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, Loscertales J, Kryachok I, Kłoczko J, Rekhtman G, Homenda W, Błoński JZ, McKeown A, Gorczyca MM, Carey JL, Chang CN, Lisby S, Gupta IV, Grosicki S.
    Leuk Lymphoma; 2017 May 09; 58(5):1084-1093. PubMed ID: 27731748
    [Abstract] [Full Text] [Related]

  • 54. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S.
    J Clin Oncol; 2010 Oct 10; 28(29):4473-9. PubMed ID: 20697090
    [Abstract] [Full Text] [Related]

  • 55. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
    Michallet M, Socié G, Mohty M, Sobh M, Bay JO, Morisset S, Labussière-Wallet H, Tabrizi R, Milpied N, Bordigoni P, El-Cheikh J, Blaise D.
    Exp Hematol; 2013 Feb 10; 41(2):127-33. PubMed ID: 23089183
    [Abstract] [Full Text] [Related]

  • 56. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
    Herishanu Y, Tadmor T, Braester A, Bairey O, Aviv A, Rahimi-Levene N, Fineman R, Levi I, Yuklea M, Ruchlemer R, Shvidel L, Polliack A.
    Hematol Oncol; 2019 Apr 10; 37(2):185-192. PubMed ID: 30756414
    [Abstract] [Full Text] [Related]

  • 57. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
    Panovská A, Smolej L, Lysák D, Brychtová Y, Šimkovič M, Motyčková M, Vodárek P, Lindtnerová M, Trbušek M, Malčíková J, Pospíšilová Š, Mayer J, Doubek M.
    Eur J Haematol; 2013 Jun 10; 90(6):479-85. PubMed ID: 23506191
    [Abstract] [Full Text] [Related]

  • 58. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
    Gozzetti A, Candi V, Fabbri A, Schiattone L, Cencini E, Lauria F, Frasconi A, Crupi R, Raspadori D, Papini G, Defina M, Bartalucci G, Bocchia M.
    Leuk Res; 2014 Aug 10; 38(8):891-5. PubMed ID: 24934847
    [Abstract] [Full Text] [Related]

  • 59. [Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
    Zagoskina TP, Tkachenko SB, Golubeva ME, Kudriavtseva AV, Isaeva NV, Malykh OV.
    Ter Arkh; 2010 Aug 10; 82(1):35-9. PubMed ID: 20364698
    [Abstract] [Full Text] [Related]

  • 60. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
    Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF.
    Clin Lymphoma Myeloma; 2005 Sep 10; 6(2):136-9. PubMed ID: 16231852
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 59.